Roberta Scalise

Roberta Scalise

Auto-generated profile, based on publicly available information

Roberta Scalise

Department of Paediatric Neurology, Catholic University, Rome, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMarika Pane
Marika Pane
EMElena Stacy Mazzone
Elena Stacy Mazzone
SSSerena Sivo
Serena Sivo
MSMaria Pia Sormani
Maria Pia Sormani
SMSonia Messina
Sonia Messina
EMEugenio Mercuri
Eugenio Mercuri
The 6 minute walk test has been recently chosen as the primary outcome measure in international multicenter clinical trials in Duchenne muscular dystrophy ambulant patients. The aim of the study was to assess the spectrum of changes at 3 years in the individual measures, their correlation with steroid treatment, age and 6 minute walk test values at baseline. Ninety-six patients from 11 centers were assessed at baseline and 12, 24 and 36 months after baseline using the 6 minute walk test and the North Star Ambulatory Assessment. Three boys (3%) lost the ability to perform the 6 minute walk test within 12 months, another 13 between 12 and 24 months (14%) and 11 between 24 and 36 months (12%). The 6 minute walk test showed an average overall decline of −15.8 (SD 77.3) m at 12 months, of −58.9 (SD 125.7) m at 24 months and −104.22 (SD 146.2) m at 36 months. The changes were significantly different in the two baseline age groups and according to the baseline 6 minute walk test values (below and above 350 m) (p<0.001). The changes were also significantly different according to steroid treatment (p = 0.01). Similar findings were found for the North Star Ambulatory Assessment. These are the first 36 month longitudinal data using the 6 minute walk test and North Star Ambulatory Assessment in Duchenne muscular dystrophy. Our findings will help not only to have a better idea of the progression of the disorder but also provide reference data that can be used to compare with the results of the long term extension studies that are becoming available.

11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMElena Stacy Mazzone
Elena Stacy Mazzone
MPMarika Pane
Marika Pane
MSMaria Pia Sormani
Maria Pia Sormani
RSRoberta Scalise
Roberta Scalise
ABangela berardinelli
angela berardinelli
EMEugenio Mercuri
Eugenio Mercuri
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to identify possible early markers of loss of ambulation. One hundred and thirteen patients (age range 4.1–17, mean 8.2) fulfilled the inclusion criteria, 67 of the 113 were on daily and 40 on intermittent steroids, while 6 were not on steroids. All were assessed using the 6 Minute Walk Test (6MWT), the North Star Ambulatory Assessment (NSAA) and timed test. On the 6MWT there was an average overall decline of −22.7 (SD 81.0) in the first year and of −64.7 (SD 123.1) in the second year. On the NSAA the average overall decline was of −1.86 (SD 4.21) in the first year and of −2.98 (SD 5.19) in the second year. Fourteen children lost ambulation, one in the first year and the other 13 in the second year of the study. A distance of at least 330 meters on the 6MWT, or a NSAA score of 18 at baseline reduced significantly the risk of losing ambulation within 2 years. These results can be of help at the time of using inclusion criteria for a study in ambulant patients in order to minimize the risk of patients who may lose ambulation within the time of the trial.

1 March 2014 in Neuromuscular Disorders
Verified
Journal Article
Open access
MPMarika Pane
Marika Pane
EMElena S. Mazzone
Elena S. Mazzone
LFLavinia Fanelli
Lavinia Fanelli
RSRoberto De Sanctis
Roberto De Sanctis
FBFlaviana Bianco
Flaviana Bianco
EMEugenio Mercuri
Eugenio Mercuri
The Performance of Upper Limb was specifically designed to assess upper limb function in Duchenne muscular dystrophy. The aim of this study was to assess (1) a cohort of typically developing children from the age of 3years onwards in order to identify the age when the activities assessed in the individual items are consistently achieved, and (2) a cohort of 322 Duchenne children and young adults to establish the range of findings at different ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to 25years old. A full score was consistently achieved by the age of 5years. In the Duchenne cohort there was early involvement of the proximal muscles and a proximal to distal progressive involvement. The scale was capable of measuring small distal movements, related to activities of daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials.

1 June 2013 in Neuromuscular Disorders
Verified
Journal Article
Closed access
MPMarika Pane
Marika Pane
RSRoberta Scalise
Roberta Scalise
ABangela berardinelli
angela berardinelli
GDGrazia D’aNgelo
Grazia D’aNgelo
VRValeria Ricotti
Valeria Ricotti
EMEugenio Mercuri
Eugenio Mercuri

8 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMarika Pane
Marika Pane
EMElena S Mazzone
Elena S Mazzone
MSMaria Pia Sormani
Maria Pia Sormani
SMSonia Messina
Sonia Messina
GVGianluca Vita
Gianluca Vita
EMEugenio Mercuri
Eugenio Mercuri
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are specifically targeting distinct groups of mutations, such as deletions eligible for skipping of individual exons. The aim of this observational study was to establish whether patients with distinct groups of mutations have different profiles of changes on the 6 minute walk test (6MWT) over a 12 month period. The 6MWT was performed in 191 ambulant DMD boys at baseline and 12 months later. The results were analysed using a test for heterogeneity in order to establish possible differences among different types of mutations (deletions, duplications, point mutations) and among subgroups of deletions eligible to skip individual exons. At baseline the 6MWD ranged between 180 and 560,80 metres (mean 378,06, SD 74,13). The 12 month changes ranged between −325 and 175 (mean −10.8 meters, SD 69.2). Although boys with duplications had better results than those with the other types of mutations, the difference was not significant. Similarly, boys eligible for skipping of the exon 44 had better baseline results and less drastic changes than those eligible for skipping exon 45 or 53, but the difference was not significant. even if there are some differences among subgroups, the mean 12 month changes in each subgroup were all within a narrow Range: from the mean of the whole DMD cohort. This information will be of help at the time of designing clinical trials with small numbers of eligible patients.

1 January 2015 in Neuromuscular Disorders
Verified
Journal Article
Closed access
RSRoberto De Sanctis
Roberto De Sanctis
MPMarika Pane
Marika Pane
SSSerena Sivo
Serena Sivo
VRValeria Ricotti
Valeria Ricotti
GBGiovanni Baranello
Giovanni Baranello
EMEugenio Mercuri
Eugenio Mercuri